
Biogen's investigational drug diranersen demonstrated a 38% slowing of clinical decline at two years in early Alzheimer's patients, with the 60 mg twice-yearly dose showing the strongest benefits across multiple cognitive and functional measures. Presented at the CTAD 2026 conference, the Phase 2 CELIA study results highlight increasing clinical benefit over time and a favorable safety profile, supporting further development toward a Phase 3 trial. This drug targets tau protein, a key factor in Alzheimer's progression, offering a novel therapeutic approach. While promising, diranersen remains investigational and not yet approved for use.
Biogen's stock price on Pluang is currently at USD 250.33, close to its 52-week high of USD 254.87 as of Nov 18, 2026 05:02 WIB, showing a slight 0.52% decline in the last day. This proximity to the yearly peak contrasts with its 52-week low of USD 164.42, indicating strong investor interest despite the minor daily dip. The stock's market cap stands at $37.20 billion, with all recent Pluang order activity being buys, reflecting continued confidence in Biogen's prospects.